ZLB Behring Releases Plasma Derivatives Anthrobin P1500.Tokyo, Japan, Apr 17, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - ZLB ZLB Zero Length Body ZLB Zero Length Bit Behring announced on April 14 that it has launched Anthronbin P1500 Injection, a new item in its plasma derivatives series. The new product, which is a human antithrombin III concentrate, is indicated for the treatment of thrombosis associated with congenital antithrombin III deficiency antithrombin III deficiency Congenital antithrombin III deficiency An AD condition characterized by ↑ risk of DVT and PE. See Antithrombin III. as well as disseminated intravascular coagulation disseminated intravascular coagulation n. Abbr. DIC A hemorrhagic disorder that occurs following the uncontrolled activation of clotting factors and fibrinolytic enzymes throughout small blood vessels, resulting in tissue necrosis and . Available in 1500 IU per syringe, the product helps simplify the drug preparation process while reducing the burden on medical staff and the risk of infection and contamination. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion